Filing Flows › RenovoRx (RNXT) › Guidance & outlook
RenovoRx (RNXT) guidance and outlook
RenovoRx (RNXT) reaffirmed its guidance on Nov 5, 2026: Revenue $3.8M–$4.2M for FY2026; Revenue +241% to +286% for FY2026. RenovoRx's 10-Q filed Nov 5, 2026 makes 49 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $3.8M–$4.2M | reaffirmed |
| Revenue | FY2026 | +241% to +286% | reaffirmed |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 5, 2026
- Our patented TAMP platform , utilizing RenovoCath, is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor locally, while potentially minimizing a therapy’s toxicities versus systemic intravenous chemotherapy.
- Our novel approach to targeted drug-delivery offers the potential for improved efficacy, safety, and tolerability, and our mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of therapeutic agents.
- As the TIGeR-PaC study progressed, we received unsolicited (and subsequently solicited) feedback from oncologists, surgeons, and interventional radiologists highlighting strong interest in our technology, indicating a demand and commercial opportunity for targeted delivery of diagnostic and/or therapeutic agents.
- And in both cases, we believe that novel improved therapies could make the TAMP targeted drug-delivery platform even more valuable.
- Our continued strong quarterly performance supports management's belief that our 2026 revenue will exceed our original full-year forecast.
- This outlook is driven by more active commercial cancer center customers, more patients treated via procedures with RenovoCath, and repeat ordering across our existing customer base.
- Based on its current customer pipeline and trends to date, we remain on target to deliver full year 2026 revenue in the range of $3.75 million to $4.25 million.
- We remain confident in our ability to meet the year-end 2026 target of 36 active commercial cancer centers as we continue to activate centers in the commercial funnel and convert sites from its fully enrolled Phase III TIGeR-PaC trial to active centers.
- We continue to estimate that the initial total addressable market (TAM) for RenovoCath as a stand-alone device could translate into an approximately $400 million peak annual U.S. sales opportunity for RenovoRx.
- TIGeR-PaC is designed to evaluate whether our patented method of targeted delivery of the chemotherapy gemcitabine improves patient survival, safety, and tolerability compared to the standard of care, systemic (intravenous) chemotherapy gemcitabine + Abraxane.
- We anticipate initial top-line data from TIGeR-PaC in the second half of 2027, and expect the data readout to support and potentially expand current clinical adoption of TAMP by providing more rigorous evidence on tolerability and reduced side effects.
- The change to the 80% power calculation aligns with common practice for clinical trials and we believe this design will shorten the timeframe needed to complete the study, as well as significantly decrease its cost.
RenovoRx's latest quarter
RenovoRx, Q3 2026: revenue $1.1M (+301% year over year), operating margin -303.6%, net loss $3.6M, operating cash flow −$2.5M. The chart follows the revenue to costs, profit and cash.
Questions
Did RenovoRx raise or lower its guidance?
RenovoRx (RNXT) reaffirmed its guidance on Nov 5, 2026: Revenue $3.8M–$4.2M for FY2026; Revenue +241% to +286% for FY2026.
What does RenovoRx expect?
Our patented TAMP platform , utilizing RenovoCath, is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor locally, while potentially minimizing a therapy’s toxicities versus systemic intravenous chemotherapy. Our novel approach to targeted drug-delivery offers the potential for improved efficacy, safety, and tolerability, and our mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of therapeutic agents. As the TIGeR-PaC study progressed, we received unsolicited (and subs
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.